Natco Pharma Ltd. Results

Q2FY25 Quarterly Result Announced for Natco Pharma Ltd.

Pharmaceuticals company Natco Pharma announced Q2FY25 results Consolidated total revenue of Rs 1434.9 crore for the Q2FY25 as against Rs 1060.8 crore for the Q2FY24, reflecting a growth of 35.3%. Net profit for the period, on a consolidated basis, was Rs 676.5 crore as against Rs 369.0 crore Q2FY24, showing robust growth of about 83%. The Board of Directors has declared second interim dividend of Rs 1.50 per equity share, for FY25.

Q4FY24 Quarterly Result Announced for Natco Pharma Ltd.

Pharmaceuticals company Natco Pharma announced Q4FY24 & FY24 results: Q4FY24: Total Revenue stood at Rs 11,103 million Pharma Export Formulations at Rs 9,549 million Consolidated Total Revenue for FY24 stood at Rs 41,269 million Earnings Before Interest Tax Depreciation and Amortization stood at Rs 5,393 million for Q4FY24 and Rs 18,795 million for FY24 EBITDA Margin for Q4FY24 & FY24 was at 48.6% and 45.5% respectively Profit Before Tax for Q4FY24 at Rs 4,776 million and Rs 16,735 million for FY24 Basic and Diluted EPS for FY24 is Rs 77.34 per share Profit after tax for Q4FY24 was at Rs 3,863 million Net Profit for FY24 was at Rs 13,883 million EBITDA and EBITDA Margin includes other income Investment of USD 2 million in Cellogen Therapeutics Private Ltd., with R&D; programs involving Cell and Gene Therapy Solutions

Q1FY24 Quarterly Result Announced for Natco Pharma Ltd.

Pharmaceuticals company Natco Pharma announced Q1FY24 results: Consolidated total revenue of Rs 1,160.2 crore for Q1FY24, as against Rs 918.9 crore for Q1FY23, a growth of 26.3%. The net profit for Q1FY24, on a consolidated basis, was Rs 420.3 crore as against Rs 320.4 crore in Q1FY23, showing 31.2% growth. The company had made a provision of Rs 51.0 crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about Rs 17.0 crore towards special incentives to employees. The Board of Directors has declared an interim dividend of Rs 7/- (350%) per equity share of Rs 2/- each, for the FY24.

Q4FY23 Quarterly & FY23 Annual Result Announced for Natco Pharma Ltd.

Pharmaceuticals company Natco Pharma announced Q4FY23 & FY23 results: Consolidated total revenue of Rs 2,811.7 crore for FY23, as against Rs 2,043.8 crore for FY22, reflecting 37.6% growth. The net profit for FY23, on a consolidated basis, was Rs 715.3 crore, as against Rs 170.0 crore in FY22. The increase in revenue and profits for FY23 was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years. For Q4FY23, the company recorded a net revenue of Rs 926.9 crore, on a consolidated basis, as against Rs 610.6 crore during Q4FY22. The profit for Q4FY23 on a consolidated basis was Rs 275.8 crore, as against a loss of Rs 50.5 crore in Q4FY22.